Abstract: PO0195
Role of Glomerular Filtration Rate (GFR)-Modifying Drugs in Prevention of Anticoagulant-Related Nephropathy (ARN)
Session Information
- AKI Mechanisms - 2
October 22, 2020 | Location: On-Demand
Abstract Time: 10:00 AM - 12:00 PM
Category: Acute Kidney Injury
- 103 AKI: Mechanisms
Authors
- Brodsky, Sergey V., The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
- Medipally, Ajay kumar, The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
- Xiao, Min, The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
- Satoskar, Anjali A., The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
- Nadasdy, Tibor, The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
- Hebert, Lee A., The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
Background
Acute kidney injury (AKI) with red blood cell (RBC) tubular casts secondary to different anticoagulants has been recognized as ARN. ARN is seen in patients with underlying kidney diseases. 5/6 nephrectomy (5/6NE) animal model reproduces morphologic features of ARN. One of the possible pathogenetic mechanisms of ARN proposed to be increased GFR.
Aim of the current study was to investigate the role of GFR-modifying drugs in prevention of ARN.
Methods
5/6NE rats 3 weeks after the surgery were treated with direct thrombin inhibitor dabigatran (150mg/kg/day) and with GFR-reducing Enalapril (1.5mg/kg/dl) or GFR-increasing Albuterol (4mg/kg/day) for 7 days. Daily monitoring of serum creatinine (SCr), blood pressure and hematuria was performed. Morphology of the kidney was evaluated at day 7 after animals were euthanized .
Results
Dabigartan resulted in gradual increase in SCr (Fig 1), hematuria, acute tubular necrosis (ATN) and RBC tubular casts in all treatment groups. Neither of GFR-modifying drugs significantly changed there parameters. ATN was 0.75±0.27, 0.67±0.25 and 0.79±0.27 in Dabigatran, Dabigatran + Enalapril and Dabigartan + Albuterol treatment groups, respectively. Systolic blood pressure was reduced with Enalaprilbut did not change significanlty with Albuterol. Diastolyc blood presuure was not changed significantly with either treatment.
Conclusion
Our data indicate that GFR-modifying drugs do not prevent or aggravate ARN at least secondary to direct thrombin inhibitor.
Funding
- NIDDK Support